Cellectis (NASDAQ:CLLS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a report issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Cellectis Trading Down 2.1 %

Cellectis stock opened at $1.86 on Monday. Cellectis has a 52-week low of $0.96 and a 52-week high of $3.77. The company has a market cap of $103.39 million, a P/E ratio of -1.44 and a beta of 3.09. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. The business has a 50-day simple moving average of $2.15 and a two-hundred day simple moving average of $2.31.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The business had revenue of $9.50 million during the quarter, compared to analysts’ expectations of $6.00 million. Analysts predict that Cellectis will post -0.54 EPS for the current year.

Institutional Trading of Cellectis

Several institutional investors have recently made changes to their positions in the business. Principal Financial Group Inc. boosted its position in shares of Cellectis by 6.2% during the 1st quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company’s stock valued at $1,125,000 after acquiring an additional 24,906 shares during the last quarter. Baillie Gifford & Co. lifted its stake in Cellectis by 1.3% in the first quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company’s stock worth $2,192,000 after purchasing an additional 10,605 shares during the last quarter. XTX Topco Ltd purchased a new position in Cellectis during the 2nd quarter valued at $29,000. Long Focus Capital Management LLC grew its holdings in shares of Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares during the last quarter. Finally, First Affirmative Financial Network bought a new position in Cellectis in the 3rd quarter worth about $45,000. Hedge funds and other institutional investors own 63.90% of the company’s stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.